Advocates of the Make America Healthy Again agenda have expressed skepticism over President Donald Trump’s agreement with ...

For years, obesity rates in the US have gone in one direction: up. From the first year it was launched, Gallup’s National ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Even after Trump’s new deal, obesity drugs are still too expensive.

Recent Gallup data shows a decline in U.S. obesity rates, likely linked to widespread use of GLP-1 drugs like Ozempic and Wegovy.

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, ...

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

This is going to have unforeseen consequences for Americans if this trend continues. The post American Obesity Rates Are Now ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking ...

Many doctors and patients came to believe the rise in obesity may be all but biologically inescapable, despite the grave ...